Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments: 2018-2024

Historic Change in Acquisitions & Divestments for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $432.5 million.

  • Allogene Therapeutics' Change in Acquisitions & Divestments fell 43.61% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year decrease of 41.20%. This contributed to the annual value of $432.5 million for FY2024, which is 27.66% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Change in Acquisitions & Divestments is $432.5 million, which was down 27.66% from $597.8 million recorded in FY2023.
  • Allogene Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $728.4 million for FY2021, and its period low was $359.5 million during FY2022.
  • In the last 3 years, Allogene Therapeutics' Change in Acquisitions & Divestments had a median value of $432.5 million in 2024 and averaged $463.2 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Change in Acquisitions & Divestments plummeted by 50.65% in 2022, and later spiked by 66.31% in 2023.
  • Allogene Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $593.6 million in 2020, then climbed by 22.70% to $728.4 million in 2021, then plummeted by 50.65% to $359.5 million in 2022, then spiked by 66.31% to $597.8 million in 2023, then decreased by 27.66% to $432.5 million in 2024.